Leukaemia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People diagnosed with a specific type of acute myeloid leukaemia (AML) that has a particular genetic change called a CEBPA mutation, specifically in a part of the gene known as the bZIP domain
- People aged 15 to 54 years old
- People of any gender
- People whose general health and ability to carry out daily activities falls within an acceptable range, as measured by a standard medical scoring tool (scores 0–2 on the ECOG scale)
- People whose recent blood test results (taken within 7 days before starting treatment) show that liver function, kidney function, heart enzyme levels, and heart pumping function are all within acceptable limits
Who may not be able to join:
- People who have already received induction chemotherapy (an initial round of intensive chemotherapy) for their AML, regardless of how well it worked
- People who currently have another type of cancer in a different part of the body that requires treatment
- Women who are pregnant or breastfeeding; all participants are required to use contraception throughout the treatment period
- People with active heart problems, including uncontrolled or symptomatic chest pain, a heart attack within the last 6 months, a heart rhythm disorder requiring medication or causing serious symptoms, uncontrolled or significant heart failure, or a heart pumping function below the normal range
- People with serious active infections, specifically untreated tuberculosis or a fungal lung infection called pulmonary aspergillosis
- People whom the trial researchers consider unsuitable for participation for other reasons (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Hui Wei, MD, Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Phone: 13132507161
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Event-free survival (EFS)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.